PT - JOURNAL ARTICLE AU - Ahadova, Aysel AU - Pfuderer, Pauline L. AU - Ahtiainen, Maarit AU - Ballhausen, Alexej AU - Bohaumilitzky, Lena AU - Kösegi, Svenja AU - Müller, Nico AU - Tang, Yee Lin AU - Kosmalla, Kosima AU - Witt, Johannes AU - Endris, Volker AU - Stenzinger, Albrecht AU - von Knebel Doeberitz, Magnus AU - Bläker, Hendrik AU - Renkonen-Sinisalo, Laura AU - Lepistö, Anna AU - Böhm, Jan AU - Mecklin, Jukka-Pekka AU - Seppälä, Toni T. AU - Kloor, Matthias TI - Distinct mutational profile of Lynch syndrome colorectal cancers diagnosed under regular colonoscopy surveillance AID - 10.1101/2020.08.21.20179127 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.21.20179127 4099 - http://medrxiv.org/content/early/2020/08/24/2020.08.21.20179127.short 4100 - http://medrxiv.org/content/early/2020/08/24/2020.08.21.20179127.full AB - Background Regular colonoscopy even with short intervals does not prevent all colorectal cancers (CRC) in Lynch syndrome (LS). In the present study, we asked whether cancers detected under regular colonoscopy surveillance (incident cancers) are phenotypically different from cancers detected at first colonoscopy (prevalent cancers).Methods We analyzed clinical, histological, immunological and mutational characteristics, including panel sequencing and high through-put coding microsatellite (cMS) analysis, in 28 incident and 67 prevalent LS CRCs.Results Incident cancers presented with lower UICC and T stage compared to prevalent cancers (p< 0.0005). The majority of incident cancers (21/28) were detected after previous colonoscopy without any pathological findings. On the molecular level, incident cancers presented with a significantly lower KRAS codon 12/13 (1/23, 4.3% vs. 11/21, 52%; p = 0.0005) and pathogenic TP53 mutation frequency (0/17, 0% vs. 7/21, 33.3%; p = 0.0108,) compared to prevalent cancers; 10/17 (58.8%) incident cancers harbored one or more truncating APC mutations, all showing mutational signatures of mismatch repair (MMR) deficiency. The proportion of MMR deficiency-related mutational events was significantly higher in incident compared to prevalent CRC (p = 0.018).Conclusions LS CRC diagnosed under regular colonoscopy surveillance are biologically distinct, suggesting that the preventive effectiveness of colonoscopy in LS depends on the molecular subtypes of tumors.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialn.a.Funding StatementThe present study was performed with grant support of the Wilhelm Sander Foundation (grant number 2016.056.1), Emil Aaltonen Foundation, Finnish Medical Foundation, Sigrid Juselius Foundation, Finnish State Research Funds (VTR), the Finnish Cancer Foundation and Jane and Aatos Erkko Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided an informed and written consent, and the study was approved by the Ethics Committee of the University Hospital Heidelberg and Central Finland Hospital District Ethical Committee. The study was performed in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data presented in this manuscript are available at the Department of Applied Tumor Biology.